An Open-Label, Non-Randomised, Multicentre Study To Allow Continued Access To And Assess The Safety And Tolerability Of Azd1775 For Patients Enrolled
Posted Date: May 15, 2019
- Investigator: Trisha Wise-Draper
- Type of Study: Drug
AstraZeneca D6014C00007
Criteria:
To Be Eligible To Participate In This Study, Patients Must Have Advanced Solid Cancer For Which Ther
Keywords:
Cancer, Continued Access, D6014c00007, Phase I, Solid Tumor
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com